Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria.
Institute for Human Nutrition and Food Science, Division of Nutriinformatics, Christian-Albrechts-University of Kiel, Kiel, Germany.
Hepatol Commun. 2023 Jun 14;7(7). doi: 10.1097/HC9.0000000000000182. eCollection 2023 Jul 1.
HCC is the leading cause of cancer in chronic liver disease. A growing body of experimental mouse models supports the notion that gut-resident and liver-resident microbes control hepatic immune responses and, thereby, crucially contribute to liver tumorigenesis. However, a comprehensive characterization of the intestinal microbiome in fueling the transition from chronic liver disease to HCC in humans is currently missing.
Here, we profiled the fecal, blood, and liver tissue microbiome of patients with HCC by 16S rRNA sequencing and compared profiles to nonmalignant cirrhotic and noncirrhotic NAFLD patients.
We report a distinct bacterial profile, defined from 16S rRNA gene sequences, with reduced α-and β-diversity in the feces of patients with HCC and cirrhosis compared to NAFLD. Patients with HCC and cirrhosis exhibited an increased proportion of fecal bacterial gene signatures in the blood and liver compared to NAFLD. Differential analysis of the relative abundance of bacterial genera identified an increased abundance of Ruminococcaceae and Bacteroidaceae in blood and liver tissue from both HCC and cirrhosis patients compared to NAFLD. Fecal samples from cirrhosis and HCC patients both showed a reduced abundance for several taxa, including short-chain fatty acid-producing genera, such as Blautia and Agathobacter. Using paired 16S rRNA and transcriptome sequencing, we identified a direct association between gut bacterial genus abundance and host transcriptome response within the liver tissue.
Our study indicates perturbations of the intestinal and liver-resident microbiome as a critical determinant of patients with cirrhosis and HCC.
肝癌是慢性肝病患者癌症死亡的主要原因。越来越多的实验性小鼠模型支持这样一种观点,即肠道和肝脏常驻微生物控制着肝脏的免疫反应,并因此对肝肿瘤的发生起着至关重要的作用。然而,目前仍缺乏对人类从慢性肝病向肝癌转变过程中肠道微生物组的全面描述。
本研究通过 16S rRNA 测序对 HCC 患者的粪便、血液和肝脏组织微生物组进行了分析,并将其与非恶性肝硬化和非肝硬化非酒精性脂肪性肝病(NAFLD)患者进行了比较。
我们报告了一种独特的细菌谱,该谱是通过 16S rRNA 基因序列定义的,与非酒精性脂肪性肝病患者相比,HCC 和肝硬化患者的粪便中 α 和 β 多样性降低。与非酒精性脂肪性肝病患者相比,HCC 和肝硬化患者的血液和肝脏中粪便中细菌基因特征的比例增加。对细菌属相对丰度的差异分析发现,与非酒精性脂肪性肝病患者相比,HCC 和肝硬化患者血液和肝脏组织中 Ruminococcaceae 和 Bacteroidaceae 的丰度增加。与非酒精性脂肪性肝病患者相比,肝硬化和 HCC 患者的粪便样本中,包括短链脂肪酸产生菌在内的多个分类群的丰度降低,如 Blautia 和 Agathobacter。通过配对的 16S rRNA 和转录组测序,我们发现肠道细菌属丰度与肝脏组织中宿主转录组反应之间存在直接关联。
本研究表明,肠道和肝脏常驻微生物组的紊乱是肝硬化和 HCC 患者的一个关键决定因素。